Global Giant Cell Arteritis Therapeutics Market: Introduction
- Giant cell arteritis (GCA) is a form of vasculitis, a family of rare disorders, which is characterized by inflammation of the blood vessels that can restrict flow of blood and damage vital organs and tissues. GCA is also called temporal arteritis and it generally affects the arteries in the scalp and neck, especially the temples. It can also affect the aorta and its large branches to the head, arms, and legs. GCA is the most common form of vasculitis in adults aged over 50.
- The most common symptoms of giant cell arteritis include throbbing headaches, fever, jaw pain, vision problems, and joint pain. Early treatment is vital to prevent serious complications such as stroke or blindness.
Key Drivers of Global Giant Cell Arteritis Therapeutics Market
- Rise in prevalence of cardiovascular disorders across the world boosts the growth of the global giant cell arteritis therapeutics market. Heart disease is the leading cause of death among men, women, and people of racial and ethnic groups in the U.S. One person dies every 37 seconds in the country from cardiovascular disease.
- Increase in the geriatric population is also one of the major drivers of the global giant cell arteritis therapeutics market. According to the WHO, the proportion of the world's population over 60 years will double from about 11% in 2000 to 22% in 2050. The absolute number of people aged 60 years and above is expected to increase from 605 million to 2 billion during the same period.
- Rise in awareness and technological advancements in health care are encouraging people to opt for advanced and modern treatment procedures for treating giant cell arteritis. This is projected to fuel the growth of the global giant cell arteritis treatment market.
Are you a Start-up willing to make it big in the Business? Grab an Exclusive PDF Brochure of Giant Cell Arteritis Therapeutics Market Report
No comments:
Post a Comment